Alexander Hardy is the President and CEO of BioMarin Pharmaceutical Inc., a leading biotechnology company focused on developing and commercializing innovative therapies for serious and life-threatening rare genetic diseases. With a robust background in the pharmaceutical industry, Hardy has been instrumental in steering BioMarin towards significant growth and success. Before joining BioMarin, he held various leadership positions at major pharmaceutical companies, including Genentech, where he honed his skills in strategic planning, business development, and global operations. At BioMarin, Hardy has been pivotal in expanding the company's portfolio of treatments and advancing its mission to provide life-changing therapies to patients with rare diseases. Under his leadership, BioMarin has successfully launched several groundbreaking products, including Vimizim and Brineura, which address critical unmet medical needs. Hardy's strategic vision has also led to the expansion of BioMarin's global footprint, with increased investments in research and development, and the establishment of new facilities worldwide. His commitment to innovation and patient-centric care has solidified BioMarin's position as a leader in the rare disease therapeutic space. In addition to his role at BioMarin, Hardy is recognized in the industry for his contributions to the advancement of biotechnology. He is frequently invited to speak at international conferences and serves on several advisory boards focused on healthcare and life sciences. Hardy's leadership is characterized by a deep understanding of the scientific and commercial aspects of the pharmaceutical industry, coupled with a passion for improving the lives of patients. His dedication to excellence and innovation continues to drive BioMarin forward, making a tangible difference in the lives of those affected by rare genetic disorders.